作 者丨尹华禄 编 辑丨刘巷 6月16日盘后，奥精医疗（688613.SH）董事会沉痛公告，公司收到公司创始人、实际控制人 之一崔福斋家属通知，崔福斋于近日因病不幸逝世，享年80岁。 据奥精医疗介绍，崔福斋为公司的发展倾注了毕生心血，带领公司逐步发展壮大成为生物材 料行业领先企业、科创板上市公司，作出了巨大贡献。 奥精医疗官网显示，该公司是是一家致力于组织再生修复植入医疗器械的研发、生产和销售 的技术企业。2011年率先在国际上研制出成分和结构均与天然人体骨组织高度相似的矿化胶 原仿生骨材料，并实现了产品的临床转化和产业化。使得我国在这一医疗器械领域处于国际 地位。目前矿化胶原仿生骨系列产品广泛应用于骨科、口腔科、神经外科等领域的骨缺损修 复，现已在临床使用超百万例。 截至公告披露之日，崔福斋直接持有奥精医疗633.48万股，占总股本的4.62%，通过北京银河 九天信息咨询中心（有限合伙）间接持有35.41万股，占总股本的0.26%。崔福斋所持有的公 司股份将按法律法规办理继承手续，奥精医疗将根据后续事项进展情况及时履行信息披露义 务。 "崔福斋在公司担任首席科学家职务，不属于公司管理层，不会引起公司管理层变 ...

Core Viewpoint - The passing of Cui Fuzhai, the founder and actual controller of AoJing Medical, is a significant event for the company, but it is stated that his death will not impact the company's operations or management stability [1][4]. Group 1: Company Background - AoJing Medical (688613.SH) is a leading enterprise in the biomaterials industry and a listed company on the Sci-Tech Innovation Board, founded by Cui Fuzhai in 2004 [1][5]. - The company specializes in the research, development, production, and sales of implantable medical devices aimed at tissue regeneration and repair [5]. - AoJing Medical developed the mineralized collagen biomimetic bone material in 2011, which closely resembles natural human bone tissue, achieving clinical transformation and industrialization [5]. Group 2: Contributions of Cui Fuzhai - Cui Fuzhai held multiple academic and professional roles, including professor and doctoral supervisor at Tsinghua University, and was recognized as a fellow by several prestigious engineering societies [3][4]. - His research focused on biomaterials science and engineering, particularly in the areas of natural mineralization mechanisms of bones and teeth, and the development of biomimetic materials [4]. - Under his leadership, AoJing Medical has launched a series of patented products, including mineralized collagen artificial bone powder and membranes, which have been widely used in clinical settings [4][5]. Group 3: Shareholding and Succession - As of the announcement date, Cui Fuzhai directly held 6.3348 million shares of AoJing Medical, accounting for 4.62% of the total share capital, and indirectly held 354,100 shares through a partnership [1]. - The shares held by Cui Fuzhai will be subject to inheritance procedures according to legal regulations, and the company will fulfill its information disclosure obligations as necessary [1].

Group 1 - The core viewpoint of the articles highlights the recent performance and financial metrics of Aojing Medical, including its stock price increase and market valuation [1] - As of March 31, 2025, Aojing Medical has 7,905 shareholders, a decrease of 232 from the previous period, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - Aojing Medical specializes in high-end biomedical materials and related medical device products, with key products including BONGOLD, single-tooth anti-rotation abutments, and oral implants [1] Group 2 - The latest financial report for Q1 2025 shows Aojing Medical achieved revenue of 42.46 million yuan, a year-on-year decrease of 10.35%, and a net profit of 1.04 million yuan, down 84.99%, with a gross margin of 60.71% [1] - The company's current price-to-earnings (P/E) ratio is significantly negative at -150.60, with a price-to-book (P/B) ratio of 1.99, and a total market capitalization of 2.795 billion yuan [2] - The industry average P/E ratio is 51.00, while the median is 37.03, indicating Aojing Medical's valuation is below industry standards [2]

Core Viewpoint - The company has issued a correction to its 2024 annual report, specifically regarding the sales dependency on major customers, indicating that two of the top five customers were new in 2024, which was not previously disclosed [1][2]. Group 1: Business Performance and Strategy - In 2024, the company accelerated its market expansion, developing over 900 new hospitals, with 800 of these due to the nationwide implementation of centralized procurement for orthopedic artificial bones, resulting in a 90% increase in terminal hospitals compared to the previous year [4][5]. - The company completed the acquisition of HumanTech Dental in April 2024, entering the dental implant market and establishing a diversified distribution system, which has shown rapid growth and is expected to become a new revenue driver [5]. - The company has made significant progress in international market expansion, obtaining medical device registrations in multiple Southeast Asian and Latin American countries, which is expected to enhance its global market presence [5]. Group 2: Operational Efficiency and Cost Management - The company has optimized its production operations, establishing a new production line capable of producing 2 million boxes of mineralized collagen artificial bone repair materials annually, which supports the increased clinical demand following centralized procurement [7][8]. - In 2025, the company plans to implement cost-reduction measures, enhance internal control management, and improve operational quality by optimizing production efficiency and managing inventory effectively [8][9]. Group 3: Innovation and R&D - The company is committed to long-term R&D investments, achieving significant breakthroughs in 2024, including the registration of new medical devices and the establishment of a postdoctoral research station to foster innovation and talent development [10]. - In 2025, the company aims to expand its R&D team and enhance collaboration mechanisms to improve product competitiveness and market share [10]. Group 4: Governance and Investor Relations - The company is focused on strengthening its governance structure and decision-making processes to enhance operational efficiency and accountability [11]. - The company emphasizes the importance of investor communication and aims to improve the quality of information disclosure while ensuring stable and continuous profit distribution policies [12][13].

5月30日，奥精医疗的资金流向如下：- 主力资金净流入877.0万元；- 游资资金净流入479.45万元；- 散 户资金净流出1356.45万元。 截至2025年5月30日收盘，奥精医疗(688613)报收于18.93元，上涨0.48%，换手率6.4%，成交量8.77万 手，成交额1.68亿元。 当日关注点 交易信息汇总 公司公告汇总奥精医疗：关于2024年年度报告的更正公告 奥精医疗科技股份有限公司于2025年4月26日在上海证券交易所网站上披露了《2024年年度报告》。经 核查发现部分内容有误，现对相关情况进行更正。更正涉及第五部分报告期内主要经营情况中关于主营 业务分析的收入和成本分析中主要销售客户及主要供应商情况。更正前，公司表示报告期内向单个客户 的销售比例未超过总额的50%，前5名客户中不存在新增客户或严重依赖少数客户的情形。更正后，公 司确认报告期内向单个客户的销售比例超过总额的50%，前5名客户中存在新增客户且严重依赖少数客 户，其中客户一和客户四是2024年新增客户。公司对由此给投资者带来的不便深表歉意，并承诺将加强 定期报告编制过程中的校对工作，提高信息披露质量。除上述更正外，《2024年 ...

Financial Performance - In 2024, the company reported total revenue of 206.03 million yuan, a decrease of 9.03% year-on-year [1] - The net profit attributable to shareholders was -12.66 million yuan, compared to a profit of 54.23 million yuan in the previous year, representing a decline of 123.35% [1] - The net profit after deducting non-recurring gains and losses was -28.37 million yuan, down 210.11% from 25.77 million yuan in the previous year [1] - The net cash flow from operating activities was -19.60 million yuan, a significant drop from 51.68 million yuan in the previous year, indicating a decrease of 137.93% [1] Q1 2025 Performance - For the first quarter of 2025, the company achieved revenue of 42.46 million yuan, down 10.35% year-on-year [2] - The net profit attributable to shareholders was 1.04 million yuan, a decline of 84.99% compared to 6.94 million yuan in the same period last year [2] - The net profit after excluding non-recurring gains and losses was -2.34 million yuan, a decrease of 168.21% from 3.43 million yuan in the previous year [2] - The net cash flow from operating activities was -15.33 million yuan, worsening from -2.09 million yuan in the same period last year, reflecting a change of 633.48% [2] Company Background - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on May 21, 2021, with an initial public offering of 33.33 million shares at a price of 16.43 yuan per share [2] - The total funds raised amounted to 548 million yuan, with a net amount of 501 million yuan after deducting issuance costs [2] - The actual net amount raised was 288 million yuan less than the planned 789 million yuan, which was intended for various projects including the construction of a health technology industrial park [3] Management and Control - The actual controllers of the company are Eric Gang Hu, Cui Fuzhai, and Huang Wanlan, with Eric Gang Hu being a U.S. national and the other two being Chinese nationals without permanent residency abroad [3]

Core Points - Aojing Medical (688613) closed at 18.93 yuan on May 30, 2025, up 9.55% from the previous week [1] - The company's total market capitalization is 2.594 billion yuan, ranking 108th in the medical device sector and 4464th in the A-share market [1] Shareholder Changes - BioVeda China RMB Investment Limited reduced its holdings by 345,087 shares, accounting for 0.25% of the total share capital [1][3] - Prior to the reduction, BioVeda held 7,584,445 shares, representing 5.6% of Aojing Medical's total shares [1] - As of May 25, 2025, BioVeda's remaining shares are 7,239,358, with a holding percentage of 5.28% [1] Company Financials - Aojing Medical's 2024 annual report shows a revenue of 206,033,014.77 yuan, a decrease of 9.03% year-on-year [2] - The net profit attributable to shareholders was -12,662,162.69 yuan, a decline of 123.35% compared to the previous year [2] - The net assets attributable to shareholders increased by 1.50% to 1.402 billion yuan, while total assets grew by 0.85% to 1.539 billion yuan [2] - The company confirmed that sales to a single customer exceeded 50% of total sales during the reporting period, indicating a significant reliance on a few customers [2]

Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 500 million, representing a growth of 25% year-over-year[13]. - In 2024, the company's operating revenue decreased by 9.03% year-on-year to CNY 206,033,014.77, primarily due to the implementation of centralized procurement for orthopedic artificial bone repair materials, which led to a decline in unit ex-factory prices despite increased sales volume[19]. - The net profit attributable to shareholders was -CNY 12,662,162.69 in 2024, a decrease of 123.35% compared to the previous year, driven by increased costs and market activity expenses following the centralized procurement[21]. - The cash flow from operating activities showed a significant decline of 137.93%, resulting in a net outflow of -CNY 19,603,287.90, attributed to reduced receivables and increased operational costs[21]. - The company's total assets increased by 0.85% year-on-year, reaching CNY 1,539,163,337.61, indicating stability in asset management[20]. - The basic earnings per share for 2024 was -CNY 0.09, a decline of 121.95% from the previous year, indicating significant financial challenges[20]. - The weighted average return on equity decreased to -0.91%, down 4.99 percentage points from the previous year, highlighting reduced profitability[20]. - The company's revenue for the reporting period was approximately ¥206 million, a decrease of 9.03% compared to the previous year due to the implementation of centralized procurement, which lowered unit prices despite increased sales volume[88]. - Operating costs increased by 51.90% year-on-year, primarily due to the high costs associated with the new dental implant product line and increased sales volume of artificial bone repair materials[89]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share within the next two years[13]. - The company completed the acquisition of HumanTech Dental in 2024, expanding into the dental implant business and increasing sales personnel and marketing activities[21]. - The company is actively pursuing international market expansion, having obtained medical device registration for its artificial bone repair product "BonGold" in Malaysia and is in the registration process in Vietnam and Indonesia[56]. - The company aims to address the challenges of bone defect repair by developing ideal artificial bone repair materials with favorable physicochemical and biological properties[43]. - The company is currently involved in key national R&D projects, including the "14th Five-Year Plan" project for personalized bone regeneration materials[72]. - The company plans to accelerate overseas business development, focusing on international markets for dental implants and artificial bones, aiming for significant growth by 2025[135]. - The company will enhance domestic market marketing efforts, leveraging existing customer resources and marketing networks to increase market share and product penetration[135]. Research and Development - The company has invested RMB 50 million in R&D for innovative medical technologies, aiming to improve operational efficiency by 10%[13]. - Research and development expenses accounted for 18.82% of operating revenue, down from 20.09% in the previous year, reflecting a strategic shift in resource allocation[20]. - R&D investment intensity is among the highest in the industry, with breakthroughs including the registration of mineralized collagen/polyester artificial bone repair materials and absorbable collagen hemostatic sponges[30]. - The company has developed a series of mineralized collagen artificial bone repair products, including "BonGold," which is the first domestic artificial bone repair product to obtain FDA 510(k) market access in the U.S.[34]. - The company has initiated a national key R&D project focused on the development of biomimetic collagen-based materials for cranial defect repair, which has entered the animal testing preparation stage[58]. - The company has made significant progress in its product pipeline, with successful registration applications for mineralized collagen/polyester artificial bone repair materials and absorbable collagen hemostatic sponges[82]. - The company has established a postdoctoral research workstation approved by the Beijing Human Resources and Social Security Bureau, enhancing its innovation capabilities and talent development in biomedical materials[83]. Product Development and Innovation - New product development includes the launch of a next-generation medical device, expected to contribute an additional RMB 100 million in revenue[13]. - The company’s production capacity for mineralized collagen artificial bone repair materials reached a standardized capacity of 2 million boxes per year, supporting clinical supply and market expansion[31]. - The company has developed a hemostatic collagen sponge that received Class III medical device registration in China, enhancing its product line in regenerative medicine[71]. - The company has completed the design planning for orthopedic and oral surgical instruments, with an expected completion of one instrument by the end of 2025[64]. - The company has achieved significant progress in the development of nerve conduit and artificial dura mater, with total investments of ¥5,000.00 million and ¥1,800.00 million respectively[64]. Risk Management - The company has no significant risks that could adversely affect its operations, ensuring a stable outlook for the upcoming year[4]. - The company faces risks related to the renewal of medical device product registration certificates, which are valid for five years, potentially impacting production and operations[75]. - The company is subject to strict regulatory oversight, and any failure to adapt to changes in healthcare policies could adversely affect its operations[80]. - The company is enhancing its production and operational management to mitigate risks associated with centralized procurement and potential price declines in the orthopedic market[80]. Corporate Governance and Management - The board of directors has approved a profit distribution plan, although no dividends will be issued this year due to reinvestment strategies[5]. - The company has implemented a new incentive plan for key personnel, with multiple first-time grants of restricted shares totaling 1,016,250 shares across various executives[144]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to RMB 12.51 million[151]. - The company has a cash dividend policy that prioritizes cash distributions, aiming for a minimum of 30% of the average distributable profit over the last three years to be distributed in cash[169]. - The company has established a comprehensive welfare system, including mandatory social insurance and supplementary medical funds for employees[165]. Environmental and Social Responsibility - The company invested 7.83 million yuan in environmental protection during the reporting period[190]. - The company has established a comprehensive environmental protection management system and conducts training on environmental protection[194]. - The company actively engages in social responsibility, focusing on the needs of stakeholders and promoting sustainable development[196].

证券代码：688613 证券简称：奥精医疗 公告编号：2025-027 奥精医疗科技股份有限公司 关于2024年年度报告的更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司（以下简称"公司"）于 2025 年4月26日在上海证 券交易所网站（www.sse.com.cn）上披露了《2024年年度报告》。经事后核查发现， 因部分信息有误，现对相关内容予以更正，具体更正如下： 更正前： 五、报告期内主要经营情况之(一)主营业务分析之2、收入和成本分析之(7).主要销 售客户及主要供应商情况之A.公司主要销售客户情况 公司前五名客户 √适用 □不适用 单位：万元 币种：人民币 占年度销售总额 是否与上市公司 序号 客户名称 销售额 比例（%） 存在关联关系 合计 / 6,796.84 33.91 / □适用 √不适用 更正后： 五、报告期内主要经营情况之(一)主营业务分析之2、收入和成本分析之(7).主要销 售客户及主要供应商情况之A.公司主要销售客户情况 公司前五名客户 √适用 □不适用 单位： ...

证券代码：688613 证券简称：奥精医疗 公告编号：2025-027 奥精医疗科技股份有限公司 关于2024年年度报告的更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司（以下简称"公司"）于 2025 年4月26日在上海证 券交易所网站（www.sse.com.cn）上披露了《2024年年度报告》。经事后核查发现， 因部分信息有误，现对相关内容予以更正，具体更正如下： 更正前： 五、报告期内主要经营情况之(一)主营业务分析之2、收入和成本分析之(7).主要销 售客户及主要供应商情况之A.公司主要销售客户情况 公司前五名客户 更正后： 五、报告期内主要经营情况之(一)主营业务分析之2、收入和成本分析之(7).主要销 售客户及主要供应商情况之A.公司主要销售客户情况 1 公司前五名客户 √适用 □不适用 √适用 □不适用 单位：万元 币种：人民币 | 序号 | 客户名称 | 销售额 | 占年度销售总额 比例（%） | 是否与上市公司 存在关联关系 | | --- | --- | --- | ...